Amgen Inc. $AMGN Shares Acquired by PKO Investment Management Joint Stock Co

PKO Investment Management Joint Stock Co raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 9.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,660 shares of the medical research company’s stock after acquiring an additional 3,400 shares during the period. Amgen makes up 0.9% of PKO Investment Management Joint Stock Co’s holdings, making the stock its 22nd largest position. PKO Investment Management Joint Stock Co’s holdings in Amgen were worth $10,910,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Wealth Quarterback LLC increased its holdings in shares of Amgen by 1.6% during the third quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock valued at $624,000 after purchasing an additional 34 shares during the period. Fairvoy Private Wealth LLC lifted its holdings in Amgen by 1.1% in the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company’s stock worth $885,000 after purchasing an additional 35 shares during the period. Nicholson Wealth Management Group LLC grew its position in Amgen by 0.6% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock valued at $1,652,000 after buying an additional 35 shares in the last quarter. LS Investment Advisors LLC increased its stake in Amgen by 4.1% during the 3rd quarter. LS Investment Advisors LLC now owns 885 shares of the medical research company’s stock valued at $250,000 after buying an additional 35 shares during the period. Finally, Crown Wealth Group LLC increased its stake in Amgen by 4.0% during the 3rd quarter. Crown Wealth Group LLC now owns 910 shares of the medical research company’s stock valued at $257,000 after buying an additional 35 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on AMGN. HSBC reaffirmed a “buy” rating and issued a $425.00 price target on shares of Amgen in a research note on Wednesday, December 10th. Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. Argus increased their price target on Amgen from $310.00 to $360.00 and gave the company a “buy” rating in a research note on Tuesday, December 30th. UBS Group upgraded Amgen to a “strong-buy” rating in a research report on Wednesday, January 7th. Finally, DZ Bank upped their price objective on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $338.55.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the sale, the executive vice president directly owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 10,908 shares of company stock valued at $3,674,966. 0.69% of the stock is currently owned by corporate insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $325.54 on Tuesday. The company has a market capitalization of $175.30 billion, a PE ratio of 25.16, a price-to-earnings-growth ratio of 2.97 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The stock has a fifty day moving average of $330.33 and a 200-day moving average of $304.99. Amgen Inc. has a one year low of $261.28 and a one year high of $346.38.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. The business had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the firm posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is presently 73.57%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.